Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The 78th American Academy of Neurology (AAN) Annual Meeting took place in Chicago, IL, from April 18-22, 2026. This meeting brought together the global neurology community to share education and advances across all major neurology disciplines. Check out our content related to dementia below, and head over to VJNeurology.com to see our full coverage.

AAN 2026

The 78th American Academy of Neurology (AAN) Annual Meeting
18–22 April 2026 | Chicago, IL & Online

AAN 2026

The 78th American Academy of Neurology (AAN) Annual Meeting
18–22 April 2026 | Chicago, IL & Online
The 78th American Academy of Neurology (AAN) Annual Meeting took place in Chicago, IL, from April 18-22, 2026. This meeting brought together the global neurology community to share education and advances across all major neurology disciplines. Check out our content related to dementia below, and head over to VJNeurology.com to see our full coverage.
Advances in dementia care: biomarkers, Lewy body diagnostics, and emerging therapies 2:49
Advances in dementia care: biomarkers, Lewy body diagnostics, and emerging therapies
Parichita Choudhury • 19 Jun 2026
Lifestyle interventions versus anti-amyloid therapies in early AD: comparative review of RCTs 3:30
Lifestyle interventions versus anti-amyloid therapies in early AD: comparative review of RCTs
Majid Fotuhi • 15 Apr 2026
Combining lifestyle interventions and anti-amyloid therapies in Alzheimer’s disease 2:32
Combining lifestyle interventions and anti-amyloid therapies in Alzheimer’s disease
Majid Fotuhi • 15 Apr 2026
Counselling patients with MCI and early AD on the importance of lifestyle interventions 2:32
Counselling patients with MCI and early AD on the importance of lifestyle interventions
Majid Fotuhi • 15 Apr 2026
Deep learning-enhanced EEG preprocessing for early Alzheimer’s disease detection 1:29
Deep learning-enhanced EEG preprocessing for early Alzheimer’s disease detection
Nardin Samuel • 20 Apr 2026
Guidance for using blood-based biomarkers in AD: which test should be used and in which patients? 2:26
Guidance for using blood-based biomarkers in AD: which test should be used and in which patients?
Suzanne Schindler • 19 Apr 2026
White matter imaging biomarkers for cognitive decline and Alzheimer’s disease 2:46
White matter imaging biomarkers for cognitive decline and Alzheimer’s disease
Yuto Uchida • 21 Apr 2026
Diagnosing dementia with Lewy bodies: clinical features and biomarker limitations 3:16
Diagnosing dementia with Lewy bodies: clinical features and biomarker limitations
Parichita Choudhury • 19 Apr 2026
Biologic classification of Lewy body disease: insights from pathology-based cohorts 3:38
Biologic classification of Lewy body disease: insights from pathology-based cohorts
Parichita Choudhury • 19 Apr 2026
Overcoming challenges associated with interpreting blood-based biomarker findings in AD 1:46
Overcoming challenges associated with interpreting blood-based biomarker findings in AD
Suzanne Schindler • 19 Apr 2026
Convergent causal mapping of memory to identify brain stimulation targets for memory dysfunction 4:34
Convergent causal mapping of memory to identify brain stimulation targets for memory dysfunction
Calvin Howard • 19 Apr 2026
Biomarker-defined subtypes in mild cognitive impairment 2:09
Biomarker-defined subtypes in mild cognitive impairment
Christopher Gibbons • 21 Apr 2026
The content of VJDementia is intended for healthcare professionals